Klaria acquires Uppsalagruppen and becomes the owner of the patent that protects Klaria’s technology platform
Klaria Pharma Holding AB (publ) (“Klaria”) today acquires Uppsalagruppen Medical AB (“Uppsalagruppen”) and the patent that protects Klaria’s drug delivery technology. To date, Klaria has had a license from Uppsalagruppen to this patent for specific molecules. With this acquisition, Klaria will now own the patent and have full freedom to develop novel drug candidates in the future.
The transaction is structured as a share transfer agreement between the owners of Klaria and Uppsalagruppen, whereby all shares in Uppsalagruppen are acquired by Klaria. As consideration, Klaria has agreed to pay license fees and royalty payments on future earnings, substantially in line with the current license agreement between Klaria and Uppsalagruppen for Klaria’s use of the patent.
The Board is of the opinion that the acquisition, in relation to the license agreement already in place between Klaria and Uppsalagruppen, does not significantly affect Klaria or its operations, except for Klaria obtaining exclusive ownership of the patent and thereby strengthening its IP-position. Uppsalagruppen had revenues of approximately 1,2 million SEK in 2018. The company had a net result of approximately -7 million SEK due almost exclusively to depreciation write downs. At the end of 2018, the company had assets of 170 thousand SEK.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Scott Boyer, CEO Klaria Pharma Holding AB (publ)
scott.boyer@klaria.com
Tel: +46 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.